March Gladness: Vitae Rebounds With Reassuring Data In Psoriasis
This article was originally published in The Pink Sheet Daily
Executive Summary
Vitae's first-in-class ROR gamma t inhibitor shows significant reduction of PASI scores with two doses tested in Phase IIa, and a solid safety profile, despite some liver enzyme increases with the higher dose.